Investigational drug · Phase 3
Brelovitug
Also called: BJT-778, BTG
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis D Infection, Chronic Hepatitis D.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "Brelovitug"
First trial start
2025
Mar 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Brelovitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis D Infection
- Chronic Hepatitis D
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Brelovitug" as an intervention, largest first.
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Pivotal-lookingRecruiting
Mirum Pharmaceuticals, Inc.Industry
NCT07200908 · 172 participants (planned) · Start Aug 27, 2025 · Primary completion Jun 30, 2027
Drug: Brelovitug 300 mg; Bulevirtide 2 mg and Brelovitug - 300 mg · For: Chronic Hepatitis D Infection
Sites: Graz, Austria; Sankt Pölten, Austria; Brno, Czechia · 57 sites in all
- A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionPivotal-lookingActive, not recruiting
Mirum Pharmaceuticals, Inc.Industry
NCT06907290 · 150 participants (planned) · Start Mar 25, 2025 · Primary completion May 2029
Drug: Brelovitug 300 mg; Brelovitug 900 mg and 1 more · For: Chronic Hepatitis D Infection
Sites: Long Beach, California; Los Angeles, California; Chicago, Illinois · 30 sites in all
- Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtidePivotal-lookingRecruiting
Mirum Pharmaceuticals, Inc.Industry
NCT07454837 · 120 participants (planned) · Start Feb 26, 2026 · Primary completion Aug 31, 2027
Drug: Brelovitug (BJT-778); Bulevirtide · For: Chronic Hepatitis D
Sites: Graz, Austria; Innsbruck, Austria; Lilienfeld, Austria · 46 sites in all
- A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Pivotal-lookingActive, not recruiting
Mirum Pharmaceuticals, Inc.Industry
NCT07298330 · 80 participants (planned) · Start Jan 14, 2026 · Primary completion Aug 2026
Drug: Brelovitug 300 mg; Brelovitug 900 mg and 1 more · For: Chronic Hepatitis D Infection
Sites: Davis, California; Sacramento, California; San Francisco, California · 27 sites in all
Mirum Pharmaceuticals, Inc.Industry
NCT07922733
Drug: Brelovitug · For: Chronic Hepatitis, Delta Virus
Sites: Cleveland, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Integrated UHPLC-MS/MS and DrugCIPHER-Based Network Pharmacology to Identify Signature Components and Evaluate Pharmacokinetics of Biyuan Tongqiao Granules in Rats.
Wan Z, Han F, Fan X, et al. · Biomed Chromatogr 2026
- Six3 promoting the migration and neural differentiation of BMSCs via Btg2ߛmediated Akt signaling pathway activation: A therapeutic strategy for stroke.
Fu Z, Li Z, Zhang L, et al. · Int J Mol Med 2026
- Current landscape of small molecule MGMT expression inhibitors as potential resistance reversers for glioblastoma.
Wang Q, Zhang Y, Zhao L, et al. · Future Med Chem 2026
- Alcohol policy and alcohol-attributable disease burden in Eastern European Union countries, 1995 to 2023.
Månsson A, Neely R, Beekmann L, et al. · Addiction 2026
- New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure.
Herta T, Gaebler C, Wiegand J, et al. · Semin Liver Dis 2026
- Integrated bioinformatics and clinical validation of oxidative stress-associated genes in atrial fibrillation and chronic kidney disease.
Liu J, Xie Z, Yu H, et al. · Exp Ther Med 2026
Also in development for Chronic Hepatitis D Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.